@article{52378d2ede634515bbcbf46c3b9ea618,
title = "Outcomes of Repeat Boston Type 1 Keratoprosthesis Implantation",
abstract = "Purpose To describe the outcomes and prognostic characteristics of patients who had a repeat Boston type 1 keratoprosthesis (KPro) implantation. Design Retrospective case series. Methods setting: Data regarding preoperative clinical and demographic characteristics and postoperative course during initial and repeat KPro placement were collected at multiple centers across the country. patients: Forty-eight eyes underwent explantation of KPro owing to complications between September 2003 and August 2014 at 5 participating tertiary eye care centers in the United States. Of those, 36 eyes that received a subsequent replacement device were included. main outcome measures: Visual acuity (VA) outcomes and postoperative complications. Results Ocular surface disease was significantly more common in eyes that required a device explantation, compared to those that retained the device (P <.001). Sixty-seven percent of eyes (24/36) achieved VA ≥20/200 vision after the repeat KPro. The probability of these 24 eyes maintaining VA ≥20/200 after the repeat KPro was 87% at 1 year and 75% at 2 years. Predictors of the ability to maintain vision ≥20/200 following surgery were a better last-recorded vision before explantation (P =.0002) and better vision immediately after repeat KPro (P <.001). Conclusion Ocular surface disease and its complications were associated with more frequent device removal. In these patients, repeat KPro resulted in restoration of vision. A reasonable visual acuity prior to device removal was associated with favorable long-term postoperative visual acuity and retention.",
author = "Sumayya Ahmad and Mathews, {Priya M.} and Divya Srikumaran and Aldave, {Anthony J.} and Tamara Lenis and Aquavella, {James V.} and Hannush, {Sadeer B.} and Michael Belin and Akpek, {Esen Karamursel}",
note = "Funding Information: Funding/Support: No funding or grant support. Financial disclosures: Esen Karamursel Akpek is an unpaid member of the board of the Sjogren's Syndrome Foundation and Tissue Banks International; she has received payment for consultancy with GlaxoSmithKline and has a grant with Allergan for which the Wilmer Institute received funding. Anthony Aldave has received compensation from the National Eye Institute for grant review; honoraria from International Sight and Restoration Eye Bank, Emory University, Henry Ford Medical Center, and Loma Linda University for lectureship; and has received funding from ClearView HealthCare Partners for a telephone survey, Stemnion for advisory board participation, and Mededicus for round-table participation, as well as Alcon, Avellino Laboratories, and Allergan for consultancy and speakers bureaus. He has also received travel support from Thea Laboratories and stipends from law firms Fransen & Molinaro and Carroll, Kelly, Trotter, Franzen, McKenna & Peabody for expert reviews. James Aquavella receives research support from Research to Prevent Blindness, NYSTAR, the Flaum Eye Institute, University of Rochester, Allegan, Bausch and Lomb, Johnson and Johnson, and Zeiss. He has received stipends from law firms Leighton Law and Lisitz, Green, Scime and Cambria for being an expert witness. Michael Belin receives consultancy fees and travel support from OCULUS. Sadeer Hannush receives a stipend as the Medical Director of the Lions Eye Bank of Delaware Valley. Divya Srikumaran receives honoraria for lecturing at resident cataract sources from Association Acumen. The following authors have no financial disclosures: Sumayya Ahmad, Tamara Lenis, and Priya Mathews. All authors attest that they meet the current ICMJE criteria for authorship. Publisher Copyright: {\textcopyright} 2016 Elsevier Inc.",
year = "2016",
month = jan,
day = "1",
doi = "10.1016/j.ajo.2015.10.012",
language = "English (US)",
volume = "161",
pages = "181--187.e1",
journal = "American Journal of Ophthalmology",
issn = "0002-9394",
publisher = "Elsevier Inc.",
}